Pediatrics · LP-013
Amoxicillin Powder for oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-013Pediatrics
- Generic identity
- AmoxicillinPowder for oral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-013
- Generic identity
- Amoxicillin
- Presentation
- Powder for oral suspension
- Catalogue strength
- 125 mg/5 mL; 250 mg/5 mL; 400 mg/5 mL
- Catalogue pack
- Bottle for reconstitution 60 mL / 100 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: amoxicillin.
- Dosage form: powder for oral suspension.
- Proposed concentrations: 125 mg/5 mL, 250 mg/5 mL and 400 mg/5 mL.
- General proposed final-volume options: 60 mL and 100 mL.
Layer 02 · Unresolved product-specific fields
- Strength-to-final-volume/SKU mapping; do not create six combinations by cross-product.
- Exact salt/trihydrate basis and formula/excipients.
- Reconstitution water volume/steps, shaking, measuring device and after-reconstitution storage/discard period.
- Approved indication, age range, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 125 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 60 mL / 100 mL; strength-to-volume mapping not supplied | Do not infer a specific bottle size or reconstitution instruction. |
| B | 250 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 60 mL / 100 mL; strength-to-volume mapping not supplied | Do not infer a specific bottle size or reconstitution instruction. |
| C | 400 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 60 mL / 100 mL; strength-to-volume mapping not supplied | Do not infer a specific bottle size or reconstitution instruction. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Amoxicillin is a penicillin antibiotic used against susceptible bacteria. It is available in solid oral and reconstituted liquid presentations, whose concentrations and administration requirements differ. It does not treat viral illnesses such as the common cold. The clinical information here is about the ingredient and form; it is not a list of approved indications or evidence of marketing authorization for a Luang Pharma product.
Clinical context and therapeutic role
Antibiotic selection depends on the infection site, likely organism, local resistance patterns, allergy history and patient factors. Culture or other testing may help when indicated. Amoxicillin can be relevant to selected respiratory, dental or other bacterial infections, but those categories do not mean every such illness requires it. The prescriber determines whether treatment is warranted, which presentation is appropriate and when failure to improve requires reassessment.
Selected safety context
Penicillin allergy may cause serious immediate reactions, including anaphylaxis. Rash, nausea and diarrhoea can occur; severe or persistent diarrhoea, particularly with blood or fever, needs review. A history of glandular fever, kidney disease or antibiotic-associated reactions is relevant. Interactions with medicines such as methotrexate or anticoagulants require assessment. Urgent help is needed for breathing difficulty, facial swelling, widespread blistering rash or other signs of severe hypersensitivity.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This presentation is a powder intended to become an oral suspension after product-specific reconstitution. The stated concentration should be interpreted using the registered label, including the final volume. Water volume, preparation method and excipients require confirmation; another product’s instructions cannot be used as a substitute.
Reconstitution should follow the exact supplied instructions and appropriate pharmacy practice. Record the relevant preparation information and use the correct oral measuring device. Check the authorized storage conditions and period after reconstitution; no universal refrigeration rule or discard interval is assumed.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specifications/formula for each concentration.
Approved label/leaflet with exact reconstitution and after-reconstitution handling.
Strength-to-bottle/SKU matrix and packaging specification.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: AmoxicillinArchived source classification: US National Library of Medicine medicine reference | Source revision recorded: Last revised 15 May 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| NHS: About amoxicillinArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 2 June 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-013.
Professional enquiries
Request product-specific evidence for LP-013.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.